Project Grant R01AI198417
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $712K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded New York University $742,364 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate autolysin control pathways in Pseudomonas aeruginosa. The research examines how bacteria regulate cell wall-degrading enzymes (autolysins) to control their activity during cell growth and division. Pseudomonas aeruginosa serves as the model organism because it causes serious human infections...
- The National Institute of Allergy and Infectious Diseases awarded $825,054 to Trustees of Dartmouth College on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how a dual-function Type VI secretion system immunity protein affects airway microbiota composition and pathogen fitness. The research examines the T6SS effector TSET and its cognate immunity protein TSIT in Pseudomonas aeruginosa, which causes chronic respiratory infections in...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $452,375 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify transcription factors that promote pulmonary infection by opportunistic pathogens. The recipient will conduct research to determine how the transcription factor RpoN responds to environmental signals in Pseudomonas aeruginosa and Klebsiella pneumoniae, and how...
- The National Institute of Allergy and Infectious Diseases awarded $449,578 to the University of California, San Diego on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore the role of lytic polysaccharide monooxygenases in the virulence and immune evasion mechanisms of Pseudomonas aeruginosa. The research investigates chitin-binding protein D (CBPD), a highly conserved lytic polysaccharide monooxygenase that P. aeruginosa produces to resist host...
- The National Institute of Allergy and Infectious Diseases awarded $533,850 to the University of Texas at Arlington on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the pathogenesis of Staphylococcus aureus thymidine-dependent small-colony variants in cystic fibrosis patients. The research characterizes how thymidine-dependent small-colony variants, which frequently colonize CF airways following anti-folate antibiotic exposure,...
- The National Institute of Allergy and Infectious Diseases awarded Columbia University $560,455 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the assembly, function, and toxicity of R-bodies in Pseudomonas aeruginosa. R-bodies are bacterial protein structures that kill grazing protists and contribute to host colonization, damage, and virulence in P. aeruginosa, a leading cause of chronic wound and lung infections and one of...
- The National Institute of Allergy and Infectious Diseases awarded Georgia TECH Research Corp $149,190 on January 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate R-pyocins as a therapeutic approach to treat high-risk, multidrug-resistant Pseudomonas aeruginosa wound infections. The project addresses the rising prevalence of multidrug-resistant and extensively drug-resistant P. aeruginosa strains that cause acute and chronic infections from...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $431,784 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on Pseudomonas aeruginosa carriage in the gastrointestinal tract. The funded research investigates how hospitalized patients acquire P. aeruginosa colonization in the GI tract, which serves as a major reservoir for subsequent spread to other body sites and infection. The recipient will...
- The National Institute of Allergy and Infectious Diseases awarded Georgia TECH Research Corp $158,696 on November 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the evolutionary adaptation of Pseudomonas aeruginosa in response to CFTR modulator therapy in individuals with cystic fibrosis. The research characterizes genetic diversity of P. aeruginosa populations isolated from chronically infected patients on trikafta...